Key Takeaways (Executive Summary) Part I: The R&D Productivity Crisis and the AI Imperative The Economics Are Broken The math […]

How to convert raw patent filings into predictive R&D roadmaps that de-risk pipelines, price M&A targets, and identify white space

The complete operational guide for pharma IP teams, portfolio managers, and supply chain leads on converting patent intelligence into production

Part I: The $15 Billion Paradox — A Market That Grows With the Brake On The pharmaceutical excipients market is

Every day a blockbuster drug holds patent protection is worth, on average, $8.2 million in revenue. That figure makes the

Executive Summary Between 2023 and 2028, an estimated $356 billion in worldwide branded pharmaceutical sales sit exposed to patent expiration.

Executive Intelligence Brief Biosimilar development is not generic drug development with more paperwork. It is a $100M-to-$300M scientific undertaking that

Executive Summary Every month, the FDA issues a batch of Tentative Approvals (TAs) for generic drug applications. Most market participants

1. What Excipients Actually Are, and Why the Definition Undersells Them The word ‘excipient’ derives from the Latin excipere, meaning